Last reviewed · How we verify
CATUMAXOMAB
Catumaxomab is a marketed antibody that binds to a specific target on cancer cells, marking them for immune system destruction. Its key strength lies in its unique mechanism of action, which effectively engages the immune system to target cancer cells. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition.
At a glance
| Generic name | CATUMAXOMAB |
|---|---|
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
Common side effects
Key clinical trials
- Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device (NA)
- Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine (PHASE1,PHASE2)
- Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis (PHASE3)
- Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC (PHASE1)
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites (PHASE2)
- Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (PHASE2)
- Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab (PHASE2)
- Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |